Nov 19 (Reuters) – Hong Kong-listed Guangzhou Innogen Pharmaceutical said on Thursday it signed a licence agreement worth more than $1 billion with Arcera Life Sciences to commercialise its GLP-1 receptor agonist drugs used to treat patients with type 2 diabetes.
The deal will allow Abu Dhabi-based Arcera to obtain regulatory approvals and commercialise the pharmaceutical product containing Efsubaglutide Alfa for human therapeutic use in selected countries in Africa, Latin America, the Middle East and Eastern Europe, Guangzhou Innogen said.
• The China-based pharmaceutical products developer said its unit, Hong Kong Innogen Pharmaceutical, entered into the licensing deal with Arcera
• Under the deal, Innogen could receive up to $38 million in upfront and near-term milestone payments, plus sales milestones and double-digit royalties tied to annual net sales
• The board said the deal is in shareholders’ best interests, leveraging Arcera’s commercial network to accelerate the global expansion and value of Efsubaglutide Alfa
• Arcera Life Sciences is a global pharmaceutical and biotechnology firm with operations spanning Africa, Europe, and parts of Latin America
• The deal comes as global drugmakers race to secure next-generation diabetes and obesity treatments offering greater convenience, tolerability and efficacy
(Reporting by Aamir Shaik Khalid in Bengaluru; Editing by Janane Venkatraman)

